You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 39 No. 3, March 1982 TABLE OF CONTENTS
  Archives
  •  Online Features
  ARTICLES
 This Article
 •References
 •Full text PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Lipid Storage Myopathy in Infantile Pompe's Disease

Harvey B. Sarnat, MD; Sanford I. Roth, MD; James E. Carroll, MD; Barbara I. Brown, PhD; W. Thomas Dungan, MD

Arch Neurol. 1982;39(3):180-183.


Abstract

• An infant died at 8 months of age with a history of developmental regression, hypotonia, severe weakness, cardiomegaly, congestive heart failure, and hepatomegaly. A diagnosis of Pompe's disease (glycogenosis type II) was established by muscle biopsy at 5 months of age. Vacuolar myopathy involved muscle fibers of histochemical type I more than type II. Many vacuoles were filled with glycogen. In addition, increased amounts of neutral lipid were demonstrated by oil red O stain, electron microscopy, and quantitative analysis. Acid {alpha}-1,4-glucosidase activity was demonstrated to be deficient. Biochemical studies failed to determine the cause of the lipid accumulation, but demonstrated a low total concentration of carnitine in the muscle (6.37 nmole/mg of protein), associated with elevated activities of carnitine palmityltransferase and palmityl-coenzyme A dehydrogenase. Palmityl-coenzyme A synthetase activity was in the normal range.



Author Affiliations

From the Departments of Pathology (Drs Sarnat and Roth), Neurology (Dr Sarnat), and Pediatrics (Drs Sarnat and Dungan), University of Arkansas for Medical Sciences, Little Rock; and the Departments of Pediatrics, Neurology, and Neurosurgery (Dr Carroll) and Biological Chemistry (Dr Brown), Washington University School of Medicine, St Louis. Dr Sarnat is now with the Departments of Pediatrics (Neurology) and Pathology, University of Calgary Faculty of Medicine, Calgary, Alberta, Canada.


Footnotes

Accepted for publication May 13, 1981.

Read before the annual meeting of the American Association of Neuropathologists, Vancouver, British Columbia, June 9, 1981.

Reprint requests to Alberta Children's Hospital, 1820 Richmond Rd, Calgary, Alberta, Canada T2T 5C7 (Dr Sarnat).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Mutations in the acid {alpha}-glucosidase gene (M. Pompe) in a patient with an unusual phenotype
Anneser et al.
Neurology 2005;64:368-370.
ABSTRACT | FULL TEXT  

The Natural Course of Infantile Pompe's Disease: 20 Original Cases Compared With 133 Cases From the Literature
van den Hout et al.
Pediatrics 2003;112:332-340.
ABSTRACT | FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1982 American Medical Association. All Rights Reserved.